Consistent with this notion, GSK2982772, a highly specific RIPK1 inhibitor, has been developed150 and has successfully completed phase II of human clinical trials for the treatment of ulcerative colitis (NCT02903966), psoriasis (NCT02776033) and rheumatoid arthritis (NCT02858492), with an excellent safety profile151,152. This evidence concerns the gene RIPK1 and psoriasis.